This phase II trial is trying to assess how well a form of targeted therapy works for the treatment of advanced anal cancer that has spread to other parts of the body and has progressed on or after chemotherapy.
This trial is treating patients with cancer of the anal canal.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
An Open Label, Randomized Phase II Study of BI 754091 Alone or in Combination With BI 836880 in Patients With Chemotherapy Resistant, Unresectable, Metastatic Squamous Cell Carcinoma of the Anal Canal
Eligible patients will be randomised to receive BI 754091 as monotherapy or in combination with BI 836880, for the treatment of unresectable or metastatic squamous cell carcinoma of the anal canal.
Recruiting Hospitals Read More